Tenax Therapeutics (TENX)

$14.96 -0.09 (-0.60%)
Market Cap 250.92M
Revenue (ttm) 0.00
Net Income (ttm) -52.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,161,800
Avg Vol 351,908
Day's Range N/A - N/A
Shares Out 17.20M
Stochastic %K 40%
Beta 1.19
Analysts Strong Sell
Price Target $28.67

Company Profile

Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was for...

Industry: Biotechnology
Sector: Healthcare
Phone: 919 855 2100
Address:
101 Glen Lennox Drive, Suite 300, Chapel Hill, United States
LongBallBarn
LongBallBarn Apr. 10 at 9:24 AM
$TENX $SYRA $SYPR $VTVT
0 · Reply
Narutoosaka
Narutoosaka Apr. 9 at 9:45 PM
$TENX https://www.youtube.com/live/NXEmFGEurkQ?si=lTruY-KyvpqwAyv9
0 · Reply
Narutoosaka
Narutoosaka Apr. 7 at 3:46 PM
$TENX i am a buyer until hit 20s
0 · Reply
LongBallBarn
LongBallBarn Apr. 6 at 3:54 PM
$TENX New 52 wk high coming soon
0 · Reply
Narutoosaka
Narutoosaka Apr. 6 at 3:22 PM
$TENX 🤣🤣🤣
0 · Reply
SuggaSean
SuggaSean Apr. 5 at 8:43 PM
$TENX Recent selloff drivers..
0 · Reply
SagaSeeker
SagaSeeker Apr. 3 at 12:52 AM
$TENX Chronic losses + negative cash flow
1 · Reply
SagaSeeker
SagaSeeker Apr. 3 at 12:51 AM
$TENX No revenue with no business
0 · Reply
My_Lai_1968
My_Lai_1968 Apr. 1 at 11:55 PM
$TENX I began purchasing 5000 shares of TENX every month starting in 1953. I've never stopped. A nice young man who works part-time as a used car salesman told me that he'd withdraw the money for me and give it to me. That was about two weeks ago so I should be seeing him soon.
0 · Reply
enzomassimi
enzomassimi Apr. 1 at 2:54 PM
$TENX BUY
0 · Reply
Latest News on TENX
Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 10, 2026, 7:00 AM EDT - 4 weeks ago

Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference

Mar 3, 2026, 7:00 AM EST - 5 weeks ago

Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference

Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026

Feb 4, 2026, 7:00 AM EST - 2 months ago

Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026

Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment

Dec 17, 2025, 9:16 AM EST - 4 months ago

Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment

Tenax Therapeutics to Participate in Upcoming Investor Conferences

Nov 25, 2025, 7:00 AM EST - 4 months ago

Tenax Therapeutics to Participate in Upcoming Investor Conferences

Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 12, 2025, 4:05 PM EST - 5 months ago

Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF

Nov 6, 2025, 7:00 AM EST - 5 months ago

Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF

Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Nov 3, 2025, 7:00 AM EST - 5 months ago

Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF

Sep 16, 2025, 7:00 AM EDT - 7 months ago

Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF

Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025

Aug 28, 2025, 7:00 AM EDT - 8 months ago

Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025

Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 13, 2025, 4:05 PM EDT - 8 months ago

Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 4:05 PM EDT - 11 months ago

Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 25, 2025, 4:05 PM EDT - 1 year ago

Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Tenax Therapeutics Announces $25 Million Private Placement

Mar 5, 2025, 8:47 AM EST - 1 year ago

Tenax Therapeutics Announces $25 Million Private Placement

Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF

Mar 5, 2025, 8:42 AM EST - 1 year ago

Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF

Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference

Mar 3, 2025, 8:00 AM EST - 1 year ago

Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference

Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

Jan 31, 2025, 9:00 AM EST - 1 year ago

Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Nov 13, 2024, 7:00 AM EST - 1 year ago

Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference

Oct 31, 2024, 4:05 PM EDT - 1 year ago

Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference

Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement

Aug 6, 2024, 7:13 AM EDT - 1 year ago

Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement

Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

May 14, 2024, 8:00 AM EDT - 2 years ago

Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Apr 30, 2024, 7:30 AM EDT - 2 years ago

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”

Apr 9, 2024, 8:30 AM EDT - 2 years ago

Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”

Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results

Mar 28, 2024, 8:30 AM EDT - 2 years ago

Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results

Tenax Therapeutics to Present at the 36th Annual Roth Conference

Mar 12, 2024, 8:30 AM EDT - 2 years ago

Tenax Therapeutics to Present at the 36th Annual Roth Conference

Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024

Feb 29, 2024, 9:00 AM EST - 2 years ago

Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024

Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan

Feb 20, 2024, 8:30 AM EST - 2 years ago

Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan

Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering

Feb 8, 2024, 8:16 AM EST - 2 years ago

Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering

Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Feb 7, 2024, 8:01 PM EST - 2 years ago

Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Biotech stock Tenax Therapeutics more than doubled on Tuesday

Feb 6, 2024, 10:01 AM EST - 2 years ago

Biotech stock Tenax Therapeutics more than doubled on Tuesday

Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Feb 6, 2024, 8:30 AM EST - 2 years ago

Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Tenax Therapeutics Announces Reverse Stock Split

Dec 29, 2023, 8:30 AM EST - 2 years ago

Tenax Therapeutics Announces Reverse Stock Split

Tenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A.

Nov 17, 2023, 8:30 AM EST - 2 years ago

Tenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A.

Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites expected 2023

Nov 13, 2023, 8:30 AM EST - 2 years ago

Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites expected 2023

Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Jul 19, 2023, 8:30 AM EDT - 2 years ago

Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Tenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Covering Use of Oral Levosimendan (TNX-103) in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

May 31, 2023, 8:54 AM EDT - 3 years ago

Tenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Covering Use of Oral Levosimendan (TNX-103) in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Tenax Therapeutics Provides 2023 Business Update

Apr 12, 2023, 8:45 AM EDT - 3 years ago

Tenax Therapeutics Provides 2023 Business Update

Tenax Announces Issuance of U.S. Patent Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Mar 22, 2023, 8:45 AM EDT - 3 years ago

Tenax Announces Issuance of U.S. Patent Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Tenax Therapeutics Announces Pricing of Approximately $15.6 Million Public Offering

Feb 3, 2023, 8:19 AM EST - 3 years ago

Tenax Therapeutics Announces Pricing of Approximately $15.6 Million Public Offering

Tenax Granted Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)

Feb 1, 2023, 4:31 PM EST - 3 years ago

Tenax Granted Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)

Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Oct 10, 2022, 8:30 AM EDT - 3 years ago

Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Tenax Therapeutics Announces the Evaluation of Strategic Alternatives

Sep 15, 2022, 8:30 AM EDT - 3 years ago

Tenax Therapeutics Announces the Evaluation of Strategic Alternatives

Tenax Therapeutics Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension

May 23, 2022, 8:30 AM EDT - 4 years ago

Tenax Therapeutics Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension

Tenax Therapeutics Announces $8 Million PIPE Offering Priced At-the-Market under Nasdaq Rules

May 18, 2022, 8:30 AM EDT - 4 years ago

Tenax Therapeutics Announces $8 Million PIPE Offering Priced At-the-Market under Nasdaq Rules

Tenax Therapeutics Reports Fiscal Year 2021 Results and Provides Business Update

Mar 31, 2022, 8:30 AM EDT - 4 years ago

Tenax Therapeutics Reports Fiscal Year 2021 Results and Provides Business Update

Tenax Therapeutics Announces Two Presentations at Upcoming American College of Cardiology Scientific Sessions

Mar 30, 2022, 5:00 PM EDT - 4 years ago

Tenax Therapeutics Announces Two Presentations at Upcoming American College of Cardiology Scientific Sessions

Tenax Therapeutics Appoints Robyn Hunter to the Board of Directors

Jan 31, 2022, 4:10 PM EST - 4 years ago

Tenax Therapeutics Appoints Robyn Hunter to the Board of Directors

Tenax Therapeutics Granted U.S. Patent for the Subcutaneous Use of Levosimendan (TNX-102)

Jan 12, 2022, 8:30 AM EST - 4 years ago

Tenax Therapeutics Granted U.S. Patent for the Subcutaneous Use of Levosimendan (TNX-102)

Tenax Therapeutics Provides Update on TNX-102, TNX-103 and TNX-201 Clinical Programs

Jan 4, 2022, 8:30 AM EST - 4 years ago

Tenax Therapeutics Provides Update on TNX-102, TNX-103 and TNX-201 Clinical Programs

LongBallBarn
LongBallBarn Apr. 10 at 9:24 AM
$TENX $SYRA $SYPR $VTVT
0 · Reply
Narutoosaka
Narutoosaka Apr. 9 at 9:45 PM
$TENX https://www.youtube.com/live/NXEmFGEurkQ?si=lTruY-KyvpqwAyv9
0 · Reply
Narutoosaka
Narutoosaka Apr. 7 at 3:46 PM
$TENX i am a buyer until hit 20s
0 · Reply
LongBallBarn
LongBallBarn Apr. 6 at 3:54 PM
$TENX New 52 wk high coming soon
0 · Reply
Narutoosaka
Narutoosaka Apr. 6 at 3:22 PM
$TENX 🤣🤣🤣
0 · Reply
SuggaSean
SuggaSean Apr. 5 at 8:43 PM
$TENX Recent selloff drivers..
0 · Reply
SagaSeeker
SagaSeeker Apr. 3 at 12:52 AM
$TENX Chronic losses + negative cash flow
1 · Reply
SagaSeeker
SagaSeeker Apr. 3 at 12:51 AM
$TENX No revenue with no business
0 · Reply
My_Lai_1968
My_Lai_1968 Apr. 1 at 11:55 PM
$TENX I began purchasing 5000 shares of TENX every month starting in 1953. I've never stopped. A nice young man who works part-time as a used car salesman told me that he'd withdraw the money for me and give it to me. That was about two weeks ago so I should be seeing him soon.
0 · Reply
enzomassimi
enzomassimi Apr. 1 at 2:54 PM
$TENX BUY
0 · Reply
LongBallBarn
LongBallBarn Apr. 1 at 2:37 PM
$TENX $VTVT $GERN $ARTL
0 · Reply
Narutoosaka
Narutoosaka Mar. 31 at 4:50 PM
$TENX trying to shake people out 🤣🤣🤣pathetic
0 · Reply
enzomassimi
enzomassimi Mar. 31 at 2:01 PM
$TENX BUY STRONG
0 · Reply
biospeculator
biospeculator Mar. 30 at 7:44 PM
$TENX In 30 years of trading stocks I have never seen a company with 6M shares and 110% institutional ownership "suddenly" go to 17M shares and under 50% institutional ownership without no news. Market cap jumped from $14 x 6.5M shares or 90M to 250M! That's half my market cap projection if phase III is successful! And yet nobody can explain this? I have liquidated my position. GLTA
1 · Reply
squiggleburp
squiggleburp Mar. 30 at 1:04 PM
$TENX I have been waiting for a pullback. Loving the odds of a nice run here. No position yet.
0 · Reply
MrBruceWayne
MrBruceWayne Mar. 30 at 11:40 AM
🚨💎 BUY ALERT $TENX
0 · Reply
stockanalysis_
stockanalysis_ Mar. 27 at 10:33 PM
After Hours Losers: $TENX $VSA $SST $AIXI $ZDAI Download this screener: https://stockanalysis.com/markets/afterhours/losers/?ref=saveontrading
0 · Reply
Narutoosaka
Narutoosaka Mar. 27 at 8:52 PM
$TENX something is about to happen
1 · Reply
biospeculator
biospeculator Mar. 26 at 4:50 PM
$TENX OK, I admit I need some serious help. My head exploded when I noticed that now that my beloved TENX with 110% institutional ownership and just over 6M shares is now showing 17M shares and only 40% institutional ownership. Where did the other 11M shares come from? Yes, I know there is an ATM in place but 160% dilution with no announcement or share pps effect? WTF Have I lost my mind? Help!
2 · Reply
De12
De12 Mar. 25 at 10:40 PM
$TENX $IOVA $IBRX Love the Greeen!!
0 · Reply
Narutoosaka
Narutoosaka Mar. 20 at 4:11 PM
$TENX when buyout?
0 · Reply
My_Lai_1968
My_Lai_1968 Mar. 19 at 6:42 AM
$TENX My good friend, a world-renowned violinist in the Cleveland Symphony Orchestra who also cans his own tomatoes for use in his highly sought after spaghetti sauce, texted me earlier today that $23 per share by April 24 is definitely likely here. He also mentioned that one of his teenage boys slashed the tires of his Hyundai Accent because he tore up his stack of Playboy magazines.
1 · Reply